Ocular Therapeutix, Inc. - Common Stock (NQ:OCUL)

7.380 +0.180 (+2.50%)

Delayed Quote Updated: 4:00 PM EDT, Oct 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ocular Therapeutix, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Why Carnival Shares Are Trading Lower By 19%, Here Are 49 Stocks Moving In Friday's Mid-Day Session ↗

September 30, 2022

Gainers

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

September 27, 2022

Gainers

Via Benzinga

Avidity Biosciences, Kronos Worldwide And Some Other Big Stocks Moving Lower On Tuesday ↗

September 27, 2022

U.S. stocks traded lower, with the Dow Jones dropping around 180 points on Tuesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Recap: Ocular Therapeutix Q2 Earnings ↗

August 08, 2022

Ocular Therapeutix (NASDAQ:OCUL) reported its Q2 earnings results on Monday, August 8, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

Via Benzinga

Why Senti Biosciences Shares Jumped Over 50%; Here Are 79 Biggest Movers From Yesterday ↗

September 30, 2022

Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares climbed 50.7% to close at $2.11 on Thursday after B of A Securities initiated coverage on the stock with a Buy rating and $7 price target.

Via Benzinga

Why NLS Pharmaceutics Shares Dipped Over 23%; Here Are 67 Biggest Movers From Yesterday ↗

September 28, 2022

Gainers

Via Benzinga

Why Bellerophon Therapeutics Shares Are Trading Higher By 24%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session ↗

September 27, 2022

Gainers

Via Benzinga

Ocular Therapeutix's Wet AMD Candidate Shows Sustained, Comparable Clinical Activity Vs. Eylea ↗

September 27, 2022

Via Benzinga

Ocular Therapeutix™ Announces Interim 7-month Data from U.S. Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD

September 27, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ To Present Data at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting

September 22, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Why Spero Therapeutics Is Trading Higher By Over 105%; Here Are 21 Stocks Moving Premarket ↗

September 22, 2022

Gainers Spero Therapeutics, Inc. (NASDAQ: SPRO) rose 105.6% to $1.69 in pre-market trading. GSK and Spero Therapeutics announced exclusive license agreement for late-stage antibiotic asset, Tebipenem...

Via Benzinga

Ocular Therapeutix™ to Present at the H.C. Wainwright 24th Annual Global Investment Conference

September 07, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

August 10, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ Reports Second Quarter 2022 Financial Results and Business Update

August 08, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ To Report Second Quarter 2022 Financial Results

July 25, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Earnings Scheduled For August 8, 2022 ↗

August 08, 2022

Companies Reporting Before The Bell • Pyxis Tankers (NASDAQ:PXS) is likely to report earnings for its second quarter.

Via Benzinga

Ocular Therapeutix™ Announces Organizational Changes to Support Development for Retinal Diseases

June 08, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ to Present at the Jefferies Healthcare Conference

June 01, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Friday ↗

May 27, 2022

During Friday's session, 59 stocks hit new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

May 26, 2022

On Thursday, 94 companies set new 52-week lows.

Via Benzinga

Expert Ratings for Ocular Therapeutix ↗

May 10, 2022

Over the past 3 months, 4 analysts have published their opinion on Ocular Therapeutix (NASDAQ:OCUL) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding...

Via Benzinga

Ocular Therapeutix™ Reports First Quarter 2022 Financial Results and Business Update

May 09, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Earnings Scheduled For May 9, 2022 ↗

May 09, 2022

Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.

Via Benzinga

Ocular Therapeutix™ To Present Pre-Clinical Data at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting

May 03, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs ↗

May 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More ↗

May 02, 2022

Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

April 29, 2022

Gainers Ocular Therapeutix (NASDAQ:OCUL) shares moved upwards by 12.3% to $4.01 during Friday's after-market session. The company's market cap stands at $307.7 million.

Via Benzinga

Ocular Therapeutix™ to Report First Quarter 2022 Financial Results

April 26, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ to Present Pre-Clinical and Clinical Data at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

April 25, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Thursday ↗

April 21, 2022

On Thursday, 236 companies hit new 52-week lows.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.